1 results match your criteria: "Milan jSOD Immunoallergologia Azienda Ospedaliero Universitaria Careggi[Affiliation]"
Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective.
Curr Opin Allergy Clin Immunol
December 2017
aAmbulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano bPersonalized Medicine Asthma and Allergy Clinic, Humanitas Research Hospital, Humanitas University, Rozzano, Milan cDepartment of Dermato-Allergology, San Gallicano Dermatological Institute, IRCCS, Rome dDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin eSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona fUnità Operativa di Dermatologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan gDepartment of Allergy and Clinical Immunology, University of Bari, Bari hDermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena iUnit of Dermatology, Department of Biomedical, Surgical, and Dental Sciences, IRCCS Galeazzi Hospital, University of Milan, Milan jSOD Immunoallergologia Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.
Purpose Of Review: The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU.
Recent Findings: Although modern second-generation H1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients.